skip to main content

ProfessionalsAndrea K. Wahlquist Brown

Andrea K. Wahlquist Brown

Tel: +1-212-373-3008
Fax: +1-212-492-0008

Tel: +1-212-373-3008
New York

1285 Avenue of the Americas
New York, NY 10019-6064
Fax: +1-212-492-0008

Bar Admissions 
Bar Admissions 

Andrea Wahlquist Brown is a partner in the firm’s Executive Compensation Group. Andrea has over 25 years of experience with complex and high-profile executive compensation matters arising in the fast-paced practice area of mergers & acquisitions. She advises on all aspects of executive compensation, employee benefits and governance matters, in a wide range of transactions involving public company, private equity, bankruptcy estate and creditor committee clients, with an emphasis on representing public companies in strategic mergers and spin-offs, as well as initial public offerings of public companies and advisory work for public company compensation committees. She also has represented some of the largest private equity sponsors in the acquisition, operation and disposition of their portfolio companies.

Andrea is recognized as one of the leading employee benefits and executive compensation lawyers by Chambers USA, Lawdragon, The Legal 500 and The Best Lawyers in America. She was recognized as one of Mergerlinks's Top Employment Lawyers in North America in 2021, 2020 and 2019 and named the Top Female M&A Lawyer, by deal value, in North America in 2019.


Some of Andrea’s most recent experience includes:

  • Allergan in its $63 billion sale to AbbVie
  • Analog Devices in its $21 billion acquisition of Maxim Integrated Products
  • Funds managed by Apollo Global Management in their acquisition of the Accent Family of Companies
  • BCG Partners in its spin-off of Newmark Group
  • Brookfield Infrastructure Partners in its $775 million acquisition of Cyxtera in connection with its chapter 11 case
  • Inhibrx in the $2.2 billion sale of INBRX-101 to Sanofi and the related spin-off of Inhibrx's non-101 assets and liabilities, non-101 discovery pipeline and its corporate infrastructure, to create a new publicly traded company known as Inhibrx Biosciences
  • Jazz Pharmaceuticals in its $7.2 billion acquisition of GW Pharmaceuticals
  • MediPacific, a Foresite Capital Management company, in its acquisition of Pardes Biosciences
  • Medline Industries in its sale of a majority interest to a consortium made up Blackstone, Carlyle and Hellman & Friedman for $31 billion
  • Meritor in its $3.7 billion sale to Cummins
  • Neptune Retail Solutions in its take-private acquisition of Quotient Technology
  • ServiceMaster in its spin-off of Frontdoor
  • Tenneco in its $7.1 billion sale to affiliates of Apollo Global Management
  • Zendesk in its acquisition by a consortium of investors for $10.2 billion

© 2024 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy